Merck Discontinues Development of SARS-CoV-2/COVID-19 Vaccine Candidates

This decision follows Merck’s review of findings from Phase 1 clinical studies for the vaccines.

In these studies, both V590 and V591 were generally well tolerated, but the immune responses were inferior to those

seen following natural infection and those reported for other SARS-CoV-2/COVID-19 vaccines.

https://www.merck.com/news/merck-discontinues-development-of-sars-cov-2-covid-19-vaccine-candidates-continues-development-of-two-investigational-therapeutic-candidates/